DELC:CC - Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Continues Investor Outreach as Psychedelic Wellness Drug Development Advances
- Delic Holdings Corp operates in North America to advance the use of psychedelics in treating difficult conditions related to major depression, PTSD and anxiety
- The company has a three-pronged approach to promoting access and affordability for treatment drugs: conducting research in its lab facility, advancing treatment through its clinical network, and educating the public through conferences and Web-based media
- The use of psychedelic drugs to treat these mental health concerns is gaining credibility some 50 years after hallucinogenic drugs reached their peak use and were generally declared illegal
- Delic recently received Health Canada authorization to obtain 60 grams of psilocybin mushrooms for its purposes and to conduct research using other psychedelics, such as MDMA (Ecstasy), LSD, DMT (Dimitri), mescaline and 2C-B.
On April 19, 1943, a Swiss chemical researcher experienced what has come to be known as “the world’s first intentional acid trip” as he experimented with the hallucinogenic effects of lysergic acid diethylamide (“LSD“) while riding his bicycle home from work. The day subsequently became celebrated as “Bicycle Day” by the drug’s users (https://ibn.fm/WN2av).
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at http://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.